75 related articles for article (PubMed ID: 35660801)
1. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
2. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
[TBL] [Abstract][Full Text] [Related]
3. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG;
Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924
[TBL] [Abstract][Full Text] [Related]
4. THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol.
Abdulrehman J; Forté S; Tomlinson G; Solh Z; Bolster L; Sun HL; Bartolucci P; Kuo KHM
BMJ Open; 2024 Jan; 14(1):e079363. PubMed ID: 38171625
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
Muñoz AJ; Ortega L; Gutiérrez A; Gallardo E; Rubio-Rodríguez D; Rubio-Terrés C; Morón B; García-Alfonso P; Soria JM
J Med Econ; 2023; 26(1):1145-1154. PubMed ID: 37602646
[TBL] [Abstract][Full Text] [Related]
7. Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Cancer Patients with Central Venous Catheters: A Literature Review.
Abdel-Razeq H; Al-Jaghbeer MJ
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541886
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE).
Knueppel P; Bang SH; Troyer C; Barriga A; Shin J; Cadiz CL; Abdo C; McCart T; Huynh B; Stevens C; Zhou C; Yang NT; Wilson M; Pon T
Thromb Res; 2022 Dec; 220():91-96. PubMed ID: 36306678
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.
Hussaini P; Larsen TL; Ghanima W; Dahm AEA
Thromb Haemost; 2024 Apr; 124(4):351-362. PubMed ID: 37816388
[TBL] [Abstract][Full Text] [Related]
11. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
Thromb Haemost; 2024 Jan; ():. PubMed ID: 38196077
[TBL] [Abstract][Full Text] [Related]
12. Prevention of venous thromboembolism in ambulatory patients with cancer.
Khorana AA; Cohen AT; Carrier M; Meyer G; Pabinger I; Kavan P; Wells P
ESMO Open; 2020 Nov; 5(6):e000948. PubMed ID: 33229505
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of apixaban vs. enoxaparin in thromboprophylaxis after spinal stenosis and degenerative spine surgery.
Baradaran Bagheri A; Dehghani MJ; Aghajanian S
Clin Neurol Neurosurg; 2024 Apr; 239():108205. PubMed ID: 38471196
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of venous thromboembolism in ambulatory cancer patients: recent advances and practical implications.
Harrigan AM; Carrier M; Wang TF
Pol Arch Intern Med; 2024 Apr; ():. PubMed ID: 38661514
[TBL] [Abstract][Full Text] [Related]
15. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design.
O'Brien SH; Li D; Mitchell LG; Hess T; Zee P; Yee DL; Newburger JW; Sung L; Rodriguez V
Thromb Haemost; 2019 May; 119(5):844-853. PubMed ID: 30861550
[TBL] [Abstract][Full Text] [Related]
16. High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19.
Baumann Kreuziger L; Kwon T; Kasthuri RS; Wahid L; Miller PJ; Enders K; Wahed AS; Anstrom KJ; Wang TY; Ortel TL
Res Pract Thromb Haemost; 2024 May; 8(4):102417. PubMed ID: 38859949
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.
Falanga A; Ay C; Di Nisio M; Gerotziafas G; Jara-Palomares L; Langer F; Lecumberri R; Mandala M; Maraveyas A; Pabinger I; Sinn M; Syrigos K; Young A; Jordan K;
Ann Oncol; 2023 May; 34(5):452-467. PubMed ID: 36638869
[No Abstract] [Full Text] [Related]
18. Incidence and risk factors of venous thromboembolism in kidney transplantation patients: a prospective cohort study.
Zhao S; Chen H; Shi X; Tan Q; Gu B
J Thromb Thrombolysis; 2024 Feb; 57(2):278-284. PubMed ID: 38017304
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts.
Hedayat A; Soltani AE; Hakiminezhad M; Zareian F; Saneian M; Moradmand M; Abrishami S; Nodoushan MHT; Pouriayevali A; Mohebbi M; Ghorbani H
Eur J Transl Myol; 2024 Jan; 34(1):. PubMed ID: 38226554
[TBL] [Abstract][Full Text] [Related]
20. Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis.
Adrianzen-Herrera D; Giorgio K; Walker RF; Sparks AD; Gergi M; Zakai NA; Lutsey PL
Res Pract Thromb Haemost; 2024 May; 8(4):102418. PubMed ID: 38798793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
